Longstanding claims that one of the reasons for high drug prices in the US is the actions of pharmacy benefit management ... investigated by the Federal Trade Commission (FTC).

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers ... The Pharmaceutical Care Management Association, the largest ...

the Federal Trade Commission (FTC) summarized the Second Interim Staff Report (Second Report) stemming from its investigation into pharmacy benefit managers (PBMs) and their impacts on competition ...

The largest pharmacy-benefit managers hiked ... vice president of the Pharmaceutical Care Management Association, a trade association representing PBMs. The FTC analyzed data submitted by the ...

“The FTC staff’s second interim report finds that the three major pharmacy benefit managers hiked ... spoke on behalf of the Pharmaceutical Care Management Association (PCMA), a trade ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty generic drugs, according to a new ...

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

A new report from the Federal Trade Commission is uncovering what ... This reportedly occurred between 2017 and 2022. “A pharmacy benefit manager in the United States gets to get a higher ...